Member since Apr '04

Working languages:
English to Italian

marina callegari
A MD for your medical translations

Milano, Lombardia
Local time: 11:33 CET (GMT+1)

Native in: Italian Native in Italian
  • PayPal accepted
  • Send message through
Feedback from
clients and colleagues

on Willingness to Work Again info
6 positive reviews
This person is a top KudoZ point holder in English to Italian
  Display standardized information
Account type Freelance translator and/or interpreter, Identity Verified Verified member
Data security Created by Evelio Clavel-Rosales This person has a SecurePRO™ card. Because this person is not a Plus subscriber, to view his or her SecurePRO™ card you must be a Business member or Plus subscriber.
Blue Board affiliation:
Services Translation, Editing/proofreading
Specializes in:
Biology (-tech,-chem,micro-)Genetics
Medical (general)Medical: Cardiology
Medical: Health CareMedical: Instruments
Medical: PharmaceuticalsPsychology
Medical: DentistryLivestock / Animal Husbandry

KudoZ activity (PRO) PRO-level points: 3640, Questions answered: 1487, Questions asked: 59
Blue Board entries made by this user  14 entries

Payment methods accepted Wire transfer, Check, PayPal | Send a payment via ProZ*Pay
Portfolio Sample translations submitted: 2
English to Italian: Power injections
Source text - English
• Contrast media should be warmed to body temperature prior to power injection.
Warning: Failure to warm contrast media to body temperature prior to power injection may result in catheter failure.

• Vigorously flush the XXX catheter using a 10cc or larger syringe and sterile normal saline prior to and immediately following the completion of power injection studies. This will ensure the patency of the XXX catheter and prevent damage to the catheter. Resistance to flushing may indicate partial or complete catheter occlusion. Do not proceed with power injection study until occlusion has been cleared.
Warning: Failure to ensure patency of the catheter prior to power injection studies may result in catheter failure.

• Do not exceed the maximum flow rate of 5cc/sec.
Warning: Power injector machine pressure limiting feature may not prevent over pressurization of an occluded catheter.
Warning: Exceeding the maximum flow rate of 5cc/sec may result in catheter failure and/or catheter tip displacement.

• Warning: XXX catheter indication for power injection of contrast media implies the catheter’s ability to withstand the procedure, but does not imply appropriateness of the procedure for a particular patient. A suitably trained clinician is responsible for evaluating the health status of a patient as it pertains to a power injection procedure.
Translation - Italian
• Prima di effettuare l'iniezione sotto pressione, scaldare il mezzo di contrasto portandolo alla temperatura corporea.
Avvertenza: Il mancato riscaldamento dei mezzi di contrasto alla temperatura corporea prima dell'iniezione sotto pressione può comportare il mancato funzionamento del catetere.

• Con una siringa da 10 cc o più e della soluzione fisiologica sterile irrigare energicamente il catetere XXX prima e subito dopo la conclusione degli studi sulle iniezioni sotto pressione. In questo modo si garantisce la pervietà del catetere XXX e si evita di danneggiarlo. La resistenza all'irrigazione può indicare l'occlusione completa o parziale del catetere. Non procedere con lo studio sulle iniezioni sotto pressione prima di aver risolto l'occlusione.
Avvertenza: il mancato accertamento della pervietà del catetere prima degli studi sulle iniezioni sotto pressione può comportare il mancato funzionamento dello stesso.

• Non superare la velocità massima di flusso di 5 cc/sec.
Avvertenza: non è detto che con la funzione di limitazione della pressione dell'iniettore a pressione si eviti la pressurizzazione eccessiva di un catetere occluso.
Avvertenza: il superamento della velocità massima di flusso di 5 cc/sec può comportare il mancato funzionamento del catetere e/o causare lo spostamento della sua estremità.

• Avvertenza: l'indicazione all'iniezione di mezzi di contrasto sotto pressione per il catetere XXX implica che il catetere sia in grado di sopportare la procedura, ma non che la procedura sia adatta per un determinato paziente. È responsabilità di uno specialista opportunamente addestrato valutare le condizioni di salute di un paziente relativamente alla procedura di iniezione sotto pressione.

English to Italian: SmPC
Source text - English

5.1 Pharmacodynamic properties

Pharmacotherapeutic group: Other alimentary tract and metabolism products - Enzymes.
ATC code: A16AB03 agalsidase alfa.

Fabry Disease is a glycosphingolipid storage disorder that is caused by deficient activity of the lysosomal enzyme α-galactosidase A, resulting in accumulation of globotriaosylceramide (also referred to as Gb3 or CTH), the glycosphingolipid substrate for this enzyme. Agalsidase alfa catalyses the hydrolysis of Gb3, cleaving a terminal galactose residue from the molecule. Treatment with the enzyme has been shown to reduce accumulation of Gb3 in many cell types including endothelial and parenchymal cells. Agalsidase alfa has been produced in a human cell line to provide for a human glycosylation profile that can influence uptake by mannose-6-phosphate receptors on the surface of target cells.

The safety and efficacy of XXX was assessed in two randomised, double blind, placebo controlled studies and open label extension studies, in a total of forty patients with a diagnosis of Fabry Disease based on clinical and biochemical evidence. Patients received the recommended dosage of 0.2 mg/kg of XXX. Twenty-five patients completed the first study and entered an extension study. After 6 months of therapy there was a significant reduction in pain in the XXX treated patients compared with placebo (p=0.021), as measured by the Brief Pain Inventory (a validated pain measurement scale). This was associated with a significant reduction in chronic neuropathic pain medication use and number of days on pain medication. In subsequent studies, in male paediatric patients, a reduction in pain was observed after 9 and 12 months of XXX therapy compared to pre-treatment baseline.
Translation - Italian


5.1 Proprietà farmacodinamiche

Categoria farmacoterapeutica: altri farmaci dell’apparato gastrointestinale e del metabolismo – Enzimi, codice ATC: A16AB03 agalsidasi alfa.

La malattia di Fabry è un'alterazione del metabolismo dei glicosfingolipidi provocata dalla riduzione dell’attività dell’enzima lisosomiale α-galattosidasi A, che determina l'accumulo del glicosfingolipide substrato di tale enzima denominato globotriaosilceramide (anche nota come Gb3 o CTH). L’α-agalsidasi catalizza l’idrolisi della Gb3, staccando il residuo terminale di galattosio dalla molecola. Il trattamento con l’enzima ha dimostrato di ridurre l’accumulo della Gb3 in molte tipologie cellulari dell’organismo, comprese le cellule endoteliali e parenchimali. L’α-agalsidasi viene prodotta in linee cellulari umane per ottenere un enzima caratterizzato da un profilo di glicosilazione umano in grado di influenzare la captazione dei recettori per il mannosio 6 fosfato presenti sulla superficie delle cellule bersaglio.

La sicurezza e l’efficacia di XXX sono state valutate in due studi randomizzati in doppio cieco, placebo-controllati, ampliati in aperto, che hanno interessato quaranta pazienti con diagnosi positiva per la malattia di Fabry formulata sulla base di evidenze cliniche e biochimiche. Ai pazienti è stata somministrata la dose consigliata di 0,2 mg/kg di XXX. Venticinque pazienti hanno completato il primo studio e sono entrati nella fase di proseguimento della sperimentazione. Dopo 6 mesi di terapia, tra i pazienti sottoposti a trattamento con XXX si è registrata una significativa riduzione del dolore, rispetto ai pazienti trattati con placebo (p=0,021), misurata in base alla Brief Pain Inventory (una scala convalidata di misura del dolore), alla quale si è accompagnata una significativa diminuzione dell’uso su base cronica di analgesici contro il dolore neuropatico e del numero di giorni di terapia con analgesici. In studi successivi, su pazienti maschi in età pediatrica, dopo 9 e 12 mesi di terapia con XXX è stata osservata una riduzione del dolore rispetto alle condizioni basali prima del trattamento.

Experience Years of experience: 19. Registered at Apr 2000. Became a member: Apr 2004.
Credentials N/A
Memberships N/A
Software DejaVu, memoQ, Microsoft Excel, Microsoft Word, Powerpoint, Translation Workspace
CV/Resume English (PDF)
Professional practices marina callegari endorses's Professional Guidelines (v1.1).
Former Medical manager and Medical director in international pharmaceutical companies, and being a MD specialized in Clinical Pharmacology, I have been working as a medical translator EN>IT for more than 10 years.

My huge experience in this field allows me to provide accurate translations in any medical area, from Oncology to Veterinary medicine, from Orthopaedics to Neurosurgery.
Moreover, I have translated hundreds of technical manuals on medical equipments and devices.

Along with my activity as a translator I also provide editing and/or medical validation of previously translated texts in order to guarantee the medical quality of the documents brought to my attention.

I also offer to assist young translators at the beginning of their professional activity as a senior tutor, providing guidelines and practical help through an accurate editing/proofreading of their translations.
This user has earned KudoZ points by helping other translators with PRO-level terms. Click point total(s) to see term translations provided.

Total pts earned: 4048
PRO-level pts: 3640

Top languages (PRO)
German to Italian4
Italian to English4
Pts in 1 more pair >
Top general fields (PRO)
Pts in 7 more flds >
Top specific fields (PRO)
Chemistry; Chem Sci/Eng68
Biology (-tech,-chem,micro-)60
Science (general)21
Marketing / Market Research12
Pts in 10 more flds >

See all points earned >
Keywords: medicine, pharmacology, drugs, IVD, medical equipments, translation, editing, proofreading, clinical research, clinical trials, patient information sheet, informed consent forms, SPC & PIL, EMEA, FDA, medical devices, user's manuals, TRADOS, DEJA VU X, memoQ, CAT tool, oncology, cardiology, immunology, psychiatry, gastroenterology, infectious diseases, microbiology, pneumology, urology, haematology, gynaecology, dermatology, Huntington disease, glycolipid storage disorders, veterinary, radiology, immunohistochemistry, FISH, hip prosthesis, spinal systems, knee replacement, hip replacement, vaccines, hemodiafiltration, hemodialysis, transcatheter cardiac, vascular & biliary devices, resuscitation systems, nucleic acid analyzer, neuromodulation devices, cardiac valves, transcatheter heart valves, aortic bioprosthesis, CR Xray systems, non invasive ventilation systems, dentistry, nuclear medicine, glucose monotoring devices, transcription and translation of promotional/educational videoclips

Profile last updated
Jan 4

More translators and interpreters: English to Italian   More language pairs

Your current localization setting


Select a language

All of
  • All of
  • Term search
  • Jobs
  • Forums
  • Multiple search